Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Aug;82(5):678-684.
doi: 10.1002/ddr.21681. Epub 2020 May 11.

Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia

Miriam S Maes  1 , Justin Y Lu  1 , Arun K Tiwari  1   2 , Natalie Freeman  1 , Vincenzo de Luca  1   2   3 , Daniel J Müller  1   2   3 , Aristotle N Voineskos  1   2   3 , Steven G Potkin  4 , Jeffrey A Lieberman  5 , Herbert Y Meltzer  6 , Gary Remington  1   2   3 , James L Kennedy  1   2   3 , Clement C Zai  1   2   3   7
Affiliations
Multicenter Study

Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia

Miriam S Maes et al. Drug Dev Res. 2021 Aug.

Abstract

Tardive dyskinesia (TD) is a potentially irreversible movement disorder observed following long-term antipsychotic exposure. Its cause is unknown; however, a genetic component has been supported by studies of affected families. Dysbindin-1, encoded by the dystrobrevin-binding protein 1 DTNBP1 gene, has been associated with schizophrenia and is potentially involved in dopamine neurotransmission through its regulation of dopamine release and dopamine D2 receptor recycling, making it a candidate for investigation in TD. We investigated common variants across the DTNBP1 gene in our schizophrenia/patients with schizoaffective disorder of European ancestry. We found a number of DTNBP1 three-marker haplotypes to be associated with TD occurrence and TD severity (p < 0.05). These preliminary findings, if replicated in larger independent samples, would suggest that drugs targeting dysbindin-1 may be an option in the prevention and treatment of TD.

Keywords: dysbindin-1 (DTNBP1); pharmacogenetics; schizophrenia; tardive dyskinesia (TD).

PubMed Disclaimer

References

REFERENCES

    1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th edn)-text revision. Washington DC: American Psychiatric Association.
    1. Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005). Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21(2), 263-265. https://doi.org/10.1093/bioinformatics/bth457
    1. Basile, V. S., Masellis, M., Badri, F., Paterson, A. D., Meltzer, H. Y., Lieberman, J. A., … Kennedy, J. L. (1999). Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology, 21(1), 17-27. https://doi.org/10.1016/S0893-133X(98)00114-6
    1. Browne, S., Roe, M., Lane, A., Gervin, M., Morris, M., Kinsella, A., … Callaghan, E. O. (1996). Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica, 94(2), 118-124.
    1. Calle, M. L., Urrea, V., Malats, N., Van Steen, K. (2010). mbmdr: an R package for exploring gene-gene interactions associated with binary or quantitative traits. Bioinformatics, 26(17), 2198-2199.

Publication types